☆ 4.8 Article

New drug application 21-628, Certican (everolimus), for the proposed indication of prophylaxis of rejection in heart transplantation - Report from the Cardiovascular and Renal Drugs Advisory Committee, US food and Drug Administration, November 16, 2005, Rockville, Md

CIRCULATION (2006)

Journal

CIRCULATION

Volume 113, Issue 10, Pages E394-E395

Publisher

LIPPINCOTT WILLIAMS & WILKINS

DOI: 10.1161/CIRCULATIONAHA.105.607630

Keywords

drugs; immune system; heart failure; transplantation

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8

Not enough ratings

New drug application 21-628, Certican (everolimus), for the proposed indication of prophylaxis of rejection in heart transplantation - Report from the Cardiovascular and Renal Drugs Advisory Committee, US food and Drug Administration, November 16, 2005, Rockville, Md

Journal

CIRCULATION

Publisher

LIPPINCOTT WILLIAMS & WILKINS

Keywords

Categories

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

New drug application 21-628, Certican (everolimus), for the proposed indication of prophylaxis of rejection in heart transplantation - Report from the Cardiovascular and Renal Drugs Advisory Committee, US food and Drug Administration, November 16, 2005, Rockville, Md

Journal

CIRCULATION

Publisher

LIPPINCOTT WILLIAMS & WILKINS

Keywords

Categories

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Export Citation

Share Paper